Overview

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Carol Fabian, MD
Collaborator:
Lignan Research Inc.
Treatments:
Secoisolariciresinol